Multiple myeloma (MM) is a type of blood cancer that can harm the kidneys. This study aims to see if early treatment can help kidney problems in MM patients.
Patients will undergo intensive chemotherapy and possibly autoHSCT (autologous hematopoietic stem cell transplantation), which uses a patient's own stem cells to try to improve kidney function. This study will test if early treatment can help those with RIMM (Renal Impairment in Multiple Myeloma) and if certain drugs can make a difference.
To join, you must be 18 or older, have MM with kidney issues, and be willing to have the transplant. You can’t join if you have other severe kidney problems, certain cancers, or allergies to study drugs.
- Study Length: The study requires ongoing treatment and observation.
- Visits Needed: Several hospital visits for treatment and follow-ups.
- Potential Benefits: Improvement in kidney function and understanding of drug effects.
How understandable was the trial content above?
Hard to understand
Easy to understand